iDNA Genomics Public Ltd
IDNA | CSE
Overview
Corporate Details
- ISIN(s):
- CY0109800710
- LEI:
- 2549006HMJWPY9CIB812
- Country:
- Cyprus
- Address:
- Theotoki, 6, 1055 Nicosia
- Website:
- https://idnagenomics.com/en/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Our company operates in the booming industry of Precision Medicine and Genetic Analysis. Our focus is on developing and providing genetic analysis for Pharmacogenetics. Preventive Medicine and Genomics of Nutrition and Sports, with constant research activity through co-operation with universities in Greece and abroad. We specialise in Genetics and fully exploit cutting-edge scientific knowledge, to provide innovative DNA analysis services that allow everybody to access their unique genetic traits, with a personalised approach. We develop innovative and pioneering solutions by leveraging our multidimensional expertise, our scientific staff and Research & Development (R&D) department, the certified laboratories and privately owned bioinformatics analysis platform, a state-of-the-art technology and the collaboration with prestigious Universities and Research Organisations.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-03-27 16:51 |
Directors' Dealings
|
English | 11.8 KB | |
| 2025-03-24 07:54 |
Directors' Dealings
|
English | 11.8 KB | |
| 2025-03-14 07:48 |
Prospectus
|
Greek (modern) | 59.6 KB | |
| 2025-03-10 17:06 |
Directors' Dealings
|
English | 11.8 KB | |
| 2025-03-04 07:43 |
Directors' Dealings
|
English | 11.8 KB | |
| 2025-02-20 09:13 |
Prospectus
|
Greek (modern) | 210.4 KB | |
| 2025-02-20 09:13 |
Prospectus
|
Greek (modern) | 210.4 KB | |
| 2025-01-13 12:18 |
Regulatory News Service
|
English | 816.0 KB | |
| 2024-12-19 12:26 |
Business and Financial Review
|
Greek (modern) | 77.2 KB | |
| 2024-12-17 08:01 |
Directors' Dealings
|
English | 11.8 KB | |
| 2024-10-30 15:28 |
Directors' Dealings
|
English | 12.1 KB | |
| 2024-09-30 14:23 |
Interim Report
|
Greek (modern) | 130.9 KB | |
| 2024-07-02 11:21 |
Declaration of Voting Results & Voting Rights Announcements
|
Greek (modern) | 109.3 KB | |
| 2024-06-10 14:42 |
Prospectus
|
Greek (modern) | 111.8 KB | |
| 2024-04-26 14:53 |
Annual Report
|
Greek (modern) | 1.3 MB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Valneva SE | France | VLA | |
|
VENTURE LIFE GROUP PLC | United Kingdom | VLG | |
|
Vetoquinol SA | France | VETO | |
|
Vicore Pharma Holding | Sweden | VICO | |
|
Vifor Pharma AG | Switzerland | VIFN | |
|
Vimian Group AB | Sweden | VIMIAN | |
|
Virbac | France | FR000 | |
|
Vistin Pharma | Norway | VISTN | |
|
Vivesto | Sweden | VIVE | |
|
Xlife Sciences AG | Switzerland | XLS |